As Biotechnology businesses, Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and Eton Pharmaceuticals Inc. (NASDAQ:ETON), are affected by compare. This especially applies to their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Progenics Pharmaceuticals Inc.||5||14.45||N/A||-0.90||0.00|
|Eton Pharmaceuticals Inc.||7||205.84||N/A||-2.36||0.00|
Table 1 demonstrates Progenics Pharmaceuticals Inc. and Eton Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.
Table 2 shows us the net margins, return on assets and return on equity of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Progenics Pharmaceuticals Inc.||0.00%||-80.6%||-44.3%|
|Eton Pharmaceuticals Inc.||0.00%||0%||-238.9%|
Progenics Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4.8 and 4.8 respectively. The Current Ratio and Quick Ratio of its competitor Eton Pharmaceuticals Inc. are 5.9 and 5.9 respectively. Eton Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Progenics Pharmaceuticals Inc.
Ratings and Recommendations for Progenics Pharmaceuticals Inc. and Eton Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Progenics Pharmaceuticals Inc.||0||0||3||3.00|
|Eton Pharmaceuticals Inc.||0||0||0||0.00|
$10.67 is Progenics Pharmaceuticals Inc.’s consensus price target while its potential upside is 179.77%.
Insider and Institutional Ownership
Progenics Pharmaceuticals Inc. and Eton Pharmaceuticals Inc. has shares held by institutional investors as follows: 80.3% and 9.2%. About 0.1% of Progenics Pharmaceuticals Inc.’s share are held by insiders. Comparatively, 5.8% are Eton Pharmaceuticals Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Progenics Pharmaceuticals Inc.||2.09%||-9.73%||7.82%||19.56%||-35.26%||28.1%|
|Eton Pharmaceuticals Inc.||-2.56%||-18.8%||-17.7%||-1.77%||0%||-0.49%|
For the past year Progenics Pharmaceuticals Inc. has 28.1% stronger performance while Eton Pharmaceuticals Inc. has -0.49% weaker performance.
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.